Morgan Stanley’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-10,782
| Closed | -$4K | – | 6923 |
|
|
2018
Q4 | $4K | Buy |
10,782
+8,711
| +421% | +$5.42K | ﹤0.01% | 6355 |
|
|
2018
Q3 | $2K | Sell |
2,071
-1,240
| -37% | -$2.08K | ﹤0.01% | 6602 |
|
|
2018
Q2 | $8K | Buy |
3,311
+1,222
| +58% | +$2.99K | ﹤0.01% | 6363 |
|
|
2018
Q1 | $5K | Sell |
2,089
-12,120
| -85% | -$30.6K | ﹤0.01% | 6411 |
|
|
2017
Q4 | $34K | Sell |
14,209
-7,485
| -35% | -$20.7K | ﹤0.01% | 5948 |
|
|
2017
Q3 | $69K | Sell |
21,694
-4,924
| -18% | -$15.8K | ﹤0.01% | 5683 |
|
|
2017
Q2 | $107K | Buy |
26,618
+20,592
| +342% | +$89.7K | ﹤0.01% | 5610 |
|
|
2017
Q1 | $22K | Sell |
6,026
-600
| -9% | -$1.88K | ﹤0.01% | 6070 |
|
|
2016
Q4 | $14K | Buy |
6,626
+3,156
| +91% | +$11.4K | ﹤0.01% | 6093 |
|
|
2016
Q3 | $22K | Sell |
3,470
-14,089
| -80% | -$86.8K | ﹤0.01% | 5894 |
|
|
2016
Q2 | $78K | Sell |
17,559
-508,270
| -97% | -$3.32M | ﹤0.01% | 5359 |
|
|
2016
Q1 | $5.52M | Buy |
525,829
+9,825
| +2% | +$195K | ﹤0.01% | 2430 |
|
|
2015
Q4 | $15.2M | Buy |
516,004
+514,941
| +48,442% | +$15.6M | 0.01% | 1623 |
|
|
2015
Q3 | $34K | Sell |
1,063
-1,382
| -57% | -$66.1K | ﹤0.01% | 5871 |
|
|
2015
Q2 | $145K | Buy |
2,445
+1,232
| +102% | +$86.9K | ﹤0.01% | 5404 |
|
|
2015
Q1 | $130K | Sell |
1,213
-795
| -40% | -$75.8K | ﹤0.01% | 5417 |
|
|
2014
Q4 | $189K | Buy |
2,008
+465
| +30% | +$44.4K | ﹤0.01% | 5269 |
|
|
2014
Q3 | $118K | Sell |
1,543
-1,754
| -53% | -$138K | ﹤0.01% | 5406 |
|
|
2014
Q2 | $296K | Buy |
3,297
+1,388
| +73% | +$85.1K | ﹤0.01% | 4946 |
|
|
2014
Q1 | $102K | Buy |
1,909
+1,676
| +719% | +$55.3K | ﹤0.01% | 5440 |
|
|
2013
Q4 | $6K | Buy |
+233
| New | +$5.55K | ﹤0.01% | 6135 |
|
|
2013
Q3 | – | Sell |
-1,162
| Closed | -$42K | – | 5460 |
|
|
2013
Q2 | $42K | Buy |
+1,162
| New | +$43.6K | ﹤0.01% | 5218 |
|
Morgan Stanley's PTX Position: Q1 2019 in Review
Morgan Stanley sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 10,782 shares — an estimated $4K sold.
Morgan Stanley first reported a position in PTX in Q2 2013 and held it in 22 quarters. The position peaked at $15.2M in Q4 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.
- Morgan Stanley reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
- Morgan Stanley sold 10,782 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $4K.
- Morgan Stanley first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 22 quarters.
- Morgan Stanley's Pernix Therapeutics Holdings, Inc. position peaked at $15.2M in Q4 2015.
- 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.
Based on Morgan Stanley's 13F filing for Q1 2019, filed 15 May 2019.